<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ADVATE- antihemophilic factor, human recombinant 
			 </strong><br>Baxter Healthcare Corporation<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ADVATE safely and
        effectively. See full prescribing information for ADVATE.<br><br>ADVATE [Antihemophilic
        Factor (Recombinant)] <br>Lyophilized Powder for Reconstitution for Intravenous
        Injection<br>Initial U.S. Approval: 2003</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ADVATE is a recombinant antihemophilic factor indicated
                                    for use in children and adults with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>
                                    for: </p>
<dl>
<dt>•</dt>
<dd>Control and prevention of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
                                        episodes. </dd>
<dt>•</dt>
<dd>Perioperative management.</dd>
<dt>•</dt>
<dd>Routine prophylaxis to prevent or
                                        reduce the frequency of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes.</dd>
</dl>
<p class="Highlighta">ADVATE is not indicated for the treatment of von
                                    Willebrand disease. (<a href="#ID_3289bc3b-9ab8-487c-b331-01b117d2d220">1</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">For intravenous injection after
                                        reconstitution only (2)<br></span>  (<a href="#section-2">2</a>)</p>
<p class="Highlighta">Each vial of ADVATE contains the labeled amount of
                                    recombinant factor  (<a href="#section-2">2</a>)</p>
<p class="Highlighta">VIII in International Units (IU). (2.1)<br>  (<a href="#section-2">2</a>)</p>
<p class="Highlighta"><span class="Italics">Control and prevention of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
                                        episodes and perioperative management</span>  (<a href="#section-2">2</a>)</p>
<p class="Highlighta"><span class="Italics">(2.1)</span>  (<a href="#section-2">2</a>)</p>
<dl>
<dt>•</dt>
<dd>Dose (IU) = body weight (kg) x desired
                                        factor VIII rise (IU/dL or % of normal) x 0.5 (IU/kg per
                                        IU/dL).</dd>
<dt>•</dt>
<dd>Determine treatment frequency based on
                                        type of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episode. </dd>
</dl>
<p class="Highlighta"><span class="Italics">Routine Prophylaxis
                                    </span>(2.1)  (<a href="#section-2">2</a>)</p>
<dl>
<dt>•</dt>
<dd>20 to 40 IU per kg every other day (3
                                        to 4 times weekly).</dd>
<dt>•</dt>
<dd>Alternatively, use every third day
                                        dosing regimen targeted to maintain FVIII trough levels ≥
                                        1%.</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">ADVATE is available as a lyophilized powder in single-use
                                    vials containing nominally 250, 500, 1000, 1500, 2000, 3000 or
                                    4000 IU. (<a href="#ID_c1b8b04c-b2ed-4905-8805-a10ce9302281">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Do not use in patients who have life-threatening
                                    <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, to mouse or
                                    hamster protein or other constituents of the product (mannitol,
                                    trehalose, sodium chloride, histidine, Tris, calcium chloride,
                                    polysorbate 80, and/or glutathione). (<a href="#ID_6627a0bb-28ba-4b1d-84a9-607923dd9c7a">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including
                                        <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> may occur. Patients may develop <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>
                                        to mouse or hamster protein, which is present in trace
                                        amounts in the product. Should symptoms occur, discontinue
                                        treatment with ADVATE and administer appropriate treatment.
                                            (<a href="#ID_f7f1cb36-7d78-4c97-9813-858934d1b06f">5.1</a>)</dd>
<dt>•</dt>
<dd>Development of activity-neutralizing
                                        antibodies may occur. If expected plasma factor VIII
                                        activity levels are not attained, or if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is not
                                        controlled with an appropriate dose, perform an assay that
                                        measures factor VIII inhibitor concentration. (<a href="#ID_1cd0e06c-9c77-4566-9264-842e8c0edaaa">5.2</a>, <a href="#ID_04567f29-97ba-479b-821b-2a451cdb1e77">5.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<dl>
<dt>•</dt>
<dd>Serious adverse drug reactions
                                        reported are <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and factor VIII inhibitors.
                                        (6.1)</dd>
<dt>•</dt>
<dd>The most common adverse drug reactions
                                        observed in greater than 5% of patients are <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>,
                                        <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>,
                                        <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="444130" conceptname="Injury of foot">limb injury</span>, nasal
                                        congestion and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. (6.1)</dd>
</dl>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Baxter
                                    Healthcare Corporation at 1-866-888-2472 or FDA at
                                    1-800-FDA-1088 or www.fda.gov/medwatch   (<a href="#section-6">6</a>)</p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Pregnancy: No human or animal data.
                                        Use only if clearly needed. (<a href="#ID_a01ec072-abb5-458d-90e0-eb90f40e1233">8.1</a>)</dd>
<dt>•</dt>
<dd>Pediatric Use: Clearance (based on per
                                        kg body weight) is higher in the pediatric population. Dose
                                        adjustment may be needed. (<a href="#ID_17d6115b-78f3-439a-bf1b-ead359d0ad24">8.4</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 5/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Preparation and Reconstitution</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Neutralizing Antibodies</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Monitoring Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-9.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-10.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-12" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_3289bc3b-9ab8-487c-b331-01b117d2d220"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">ADVATE [Antihemophilic Factor (Recombinant)] is a recombinant
                            antihemophilic factor indicated for use in children and adults with
                            <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> (congenital <span class="product-label-link" type="condition" conceptid="4120609" conceptname="Factor VIII deficiency">factor VIII deficiency</span>) for:</p>
<dl>
<dt>•</dt>
<dd>Control and prevention of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
                                episodes.</dd>
<dt>•</dt>
<dd>Perioperative management.</dd>
<dt>•</dt>
<dd>Routine prophylaxis to prevent or reduce the
                                frequency of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes.</dd>
</dl>
<p>ADVATE is not indicated for the treatment of von Willebrand
                            disease.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_87a53055-557a-49a4-84bc-f1badb93f503"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">For intravenous injection after reconstitution
                                only.</span></p>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_c3304267-c6d5-4223-8378-1d9bcdd6dfec"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dose</h2>
<dl>
<dt>•</dt>
<dd>Dosage and duration of treatment
                                        depend on the severity of <span class="product-label-link" type="condition" conceptid="4120609" conceptname="Factor VIII deficiency">factor VIII deficiency</span>, the
                                        location and extent of the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and the patient’s
                                        clinical condition. Careful control of replacement therapy
                                        is especially important in cases of major surgery or
                                        life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes.</dd>
<dt>•</dt>
<dd>Each vial of ADVATE has the
                                        recombinant factor VIII potency in International Units (IU)
                                        stated on the label. The expected <span class="Italics">in vivo</span> peak increase in
                                        factor VIII level expressed as IU/dL of plasma or percent of
                                        normal can be estimated using the following
                                        formulas:<br>
</dd>
</dl>
<p class="First"><span class="Italics">IU/dL (or % of normal) = [total
                                        dose (IU)/body weight (kg)] x 2 [IU/dL]/[IU/kg]</span></p>
<p>OR</p>
<p><span class="Italics">Required dose (International Units)
                                        = body weight (kg) x desired factor VIII rise (IU/dL or % of
                                        normal) x 0.5 (IU/kg per IU/dL)</span><br></p>
<p>Examples (assuming patient's baseline factor VIII level
                                    is &lt; 1% of normal):</p>
<dl>
<dt>1.</dt>
<dd>A dose of 1750 IU ADVATE administered
                                        to a 70 kg patient should be expected to result in a peak
                                        post-infusion factor VIII increase of 1750 IU × {[2
                                        IU/dL]/[IU/kg]}/[70 kg] = 50 IU/dL (50% of normal).</dd>
<dt>2.</dt>
<dd>A peak level of 70% is required in a
                                        40 kg child. In this situation, the appropriate dose would
                                        be 40 kg × 70 IU/dL/{[2 IU/dL]/[IU/kg]} = 1400 IU.</dd>
<dt>•</dt>
<dd>Base the dose and frequency on the
                                        individual clinical response. Patients may vary in their
                                        pharmacokinetic (e.g., half-life, <span class="Italics">in vivo</span> recovery) and
                                        clinical responses to ADVATE. Although the dose can be
                                        estimated by the calculations above, whenever possible,
                                        perform appropriate laboratory tests including serial factor
                                        VIII activity assays. [see <span class="Italics">Warnings and Precautions</span> (5.3) <span class="Italics">and Clinical Pharmacology</span>
                                            (<a href="#ID_b259dfd3-5136-4800-b623-ead63ae5b430">12.3</a>)]</dd>
</dl>
<p><span class="Italics">Control and Prevention of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>
                                        Episodes</span></p>
<p>A guide for dosing ADVATE for the control and prevention
                                    of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes is provided in <a href="#_RefIDB86A925A61044BC7B2808E9C9CE8861F">Table
                                        1</a>. The goal of treatment is to maintain a plasma
                                    factor VIII activity level at or above the plasma levels (in %
                                    of normal or in IU/dL) outlined in <a href="#_RefIDB86A925A61044BC7B2808E9C9CE8861F">Table
                                        1</a>.</p>
<a name="_RefIDB86A925A61044BC7B2808E9C9CE8861F"></a><table width="100%">
<caption><span>Table 1 Dosing for Control and Prevention of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>
                                        Episodes </span></caption>
<col width="39%">
<col width="16%">
<col width="9%">
<col width="17%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Type of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>
                                                  Episodes</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Factor VIII Level
                                                  Required (% of normal or IU/dL)</span></p></td>
<td class="Botrule Lrule Toprule">
<p class="First"><span class="Bold">Dose<span class="Sup">1</span></span></p>
<p><span class="Bold">(IU/kg)</span></p>
</td>
<td class="Botrule Lrule Toprule"><p class="First"><span class="Bold">Frequency of Doses
                                                  (hours)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Duration of Therapy
                                                  (days)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Minor</span><br>Early <span class="product-label-link" type="condition" conceptid="76784" conceptname="Hemarthrosis">hemarthrosis</span>, mild
                                                  muscle <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or mild oral <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episode.
                                                </p></td>
<td class="Botrule Lrule" align="center"><p class="First">20-40</p></td>
<td class="Botrule Lrule"><p class="First">10-20</p></td>
<td class="Botrule Lrule">
<p class="First">12-24 </p>
<p>(Every 8 to 24 hours for patients under
                                                  the age of 6)</p>
</td>
<td class="Botrule Lrule Rrule">
<p class="First">Until the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is</p>
<p>resolved</p>
<p>(approximately 1 to 3</p>
<p>days).</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Moderate</span><br>Muscle <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
                                                  into the oral cavity, definite hemarthroses, and
                                                  known <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>. </p></td>
<td class="Botrule Lrule" align="center"><p class="First">30-60</p></td>
<td class="Botrule Lrule"><p class="First">15-30</p></td>
<td class="Botrule Lrule">
<p class="First">12-24</p>
<p>(Every 8 to 24 hours for patients under
                                                  the age of 6)</p>
</td>
<td class="Botrule Lrule Rrule">
<p class="First">Until the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is</p>
<p>resolved</p>
<p>(approximately 3 days</p>
<p>or more).</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="Bold">Major</span><br>Significant gastrointestinal
                                                  <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, intracranial, intra-abdominal or
                                                  intrathoracic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, central nervous system
                                                  <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the retropharyngeal or
                                                  retroperitoneal spaces or iliopsoas sheath,
                                                  <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>.</p></td>
<td class="Botrule Lrule" align="center"><p class="First">60-100</p></td>
<td class="Botrule Lrule"><p class="First">30-50</p></td>
<td class="Botrule Lrule">
<p class="First">8-24</p>
<p>(Every 6 to 12 hours for patients under
                                                  the age of 6)</p>
</td>
<td class="Botrule Lrule Rrule"><p class="First">Until <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is resolved.</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Perioperative Management</span></p>
<p>A guide for dosing ADVATE during surgery (perioperative
                                    management) is provided in Table 2. The goal of treatment is to
                                    maintain a plasma factor VIII activity level at or above the
                                    plasma level (in % of normal or in IU/dL) outlined in <a href="#_RefIDA35DB334DD0C437BA16A244C0FD65EDD">Table
                                        2</a>.</p>
<a name="_RefIDA35DB334DD0C437BA16A244C0FD65EDD"></a><table width="100%">
<caption><span>Table 2 Dosing for Perioperative Management </span></caption>
<col width="28%">
<col width="16%">
<col width="11%">
<col width="23%">
<col width="23%">
<thead><tr class="First Last Toprule">
<th class="Botrule Lrule" align="center" valign="top"><span class="Bold">Type of Surgery</span></th>
<th class="Botrule Lrule" align="center" valign="top">
<span class="Bold">Factor VIII Level
                                                  Required</span><br><span class="Bold">(% of normal or
                                                  IU/dL)</span>
</th>
<th class="Botrule Lrule" align="center" valign="top"><span class="Bold">Dose<span class="Sup">1
                                                  </span>(IU/kg)</span></th>
<th class="Botrule Lrule" align="center" valign="top"><span class="Bold">Frequency of Doses
                                                  (hours)</span></th>
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Duration of Therapy
                                                  (days)</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule">
<p class="First"><span class="Bold">Minor</span></p>
<p>Including tooth extraction</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">60-100</p></td>
<td class="Botrule Lrule"><p class="First">30-50</p></td>
<td class="Botrule Lrule">
<p class="First">Single dose within one hour of the
                                                  operation. </p>
<p>12-24 (as needed to control
                                                  <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>)</p>
</td>
<td class="Botrule Lrule Rrule">
<p class="First">Single dose or repeat until <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is
                                                  resolved.</p>
<p>For dental procedures, adjunctive therapy
                                                  may be considered.</p>
</td>
</tr>
<tr class="Botrule Last">
<td class="Botrule Lrule">
<p class="First"><span class="Bold">Major </span></p>
<p>Intracranial, intra-abdominal, or
                                                  intrathoracic surgery, joint replacement
                                                  surgery</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">80-120<br>(pre- and
                                                  post-operative)</p></td>
<td class="Botrule Lrule"><p class="First">40-60</p></td>
<td class="Botrule Lrule">
<p class="First">One dose preoperative to achieve 100%
                                                  activity.<br></p>
<p>Every 8-24 to keep factor VIII activity
                                                  in desired range.</p>
<p>(Every 6 to 24 hours for patients under
                                                  the age of 6)</p>
</td>
<td class="Botrule Lrule Rrule"><p class="First">Until healing is complete.</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Routine Prophylaxis</span></p>
<dl>
<dt>•</dt>
<dd>Use dose of 20 to 40 International
                                        Units of factor VIII per kg body weight every other day (3
                                        to 4 times weekly).</dd>
<dt>•</dt>
<dd>Alternatively, use every third day
                                        dosing regimen targeted to maintain FVIII trough levels ≥
                                        1%.</dd>
<dt>•</dt>
<dd>Adjust dose based on the patient’s
                                        clinical response.<span class="Sup">1,2</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9764186e-de26-41f1-8a54-00aad508955b"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Preparation and Reconstitution</h2>
<p class="First"><span class="Italics">Preparation</span></p>
<dl>
<dt>•</dt>
<dd>Do not remove ADVATE or diluent vials
                                        from the external housing. </dd>
<dt>•</dt>
<dd>Always work on a clean surface and
                                        wash your hands before performing the procedures.</dd>
<dt>•</dt>
<dd>Examine the packaging containing
                                        ADVATE to ensure no damage or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> of the lid is evident.
                                        Do not use if the lid is not completely sealed on the
                                        <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>. Do not remove ADVATE or diluent vials from the
                                        external housing. </dd>
</dl>
<p><span class="Italics">Reconstitution</span></p>
<dl>
<dt>1.</dt>
<dd>Allow the ADVATE package to reach
                                        room temperature.</dd>
<dt>2.</dt>
<dd>Open the package by <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> away the
                                        lid. Remove ADVATE from the package and verify that the
                                        expiration date on the label has not passed and the potency
                                        unit number is same as expected. Inspect parenteral drug
                                        products for discoloration and particulate matter. The
                                        ADVATE powder should be white to off-white in color and the
                                        diluent free from foreign particles. Do not use if the
                                        criteria are not met.</dd>
<dt>3.</dt>
<dd>Place the ADVATE on a flat surface
                                        with the diluent vial on top (Figure A). The diluent vial
                                        has a blue stripe. <span class="Underline">Do not
                                            remove the blue cap until instructed in a later
                                            step</span>.</dd>
<dt>4.</dt>
<dd>With one hand holding the ADVATE
                                        housing, press down firmly on the diluent vial with the
                                        other hand until the system is fully collapsed and the
                                        diluent flows down into the ADVATE vial (Figure B). Do not
                                        tilt the system until the transfer is complete.</dd>
<dt>5.</dt>
<dd>Verify that diluent transfer is
                                        complete. Swirl gently until the powder is completely
                                        dissolved (Figure C). <span class="Underline">Do not
                                            shake. Do not refrigerate after
                                            reconstitution.</span>
</dd>
</dl>
<table width="100%">
<col width="30%">
<col width="30%">
<col width="30%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center"><p class="First"><span class="Bold">Figure A</span></p></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">Figure B</span></p></td>
<td class="Rrule Toprule" align="center"><p class="First"><span class="Bold">Figure C</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center">
<a name="id1636"></a><img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-01.jpg">
</td>
<td class="Botrule" align="center">
<a name="id1639"></a><img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-02.jpg">
</td>
<td class="Botrule Rrule" align="center">
<a name="id1642"></a><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-03.jpg">
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_09acb118-627c-4381-8324-4bd26aaa4f5f"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Administration</h2>
<p class="First"><span class="Bold">For intravenous injection after
                                        reconstitution only.</span></p>
<dl>
<dt>•</dt>
<dd>Inspect parenteral drug products for
                                        particulate matter and discoloration prior to
                                        administration. The solution should be clear and colorless
                                        in appearance. If not, do not use the solution and notify
                                        Baxter immediately.</dd>
<dt>•</dt>
<dd>Administer ADVATE at room temperature
                                        within 3 hours of reconstitution. </dd>
<dt>•</dt>
<dd>Use plastic syringes with this product
                                        because proteins in the product tend to stick to the surface
                                        of glass syringes.</dd>
</dl>
<p>1. Use aseptic technique.</p>
<p>2. Remove the blue cap from the housing. Connect the
                                    syringe to the system (Figure D). <span class="Underline">Do not inject air into the ADVATE</span>.</p>
<p>3. Turn the system upside down (factor concentrate vial
                                    now on top). Draw the factor concentrate into the syringe by
                                    pulling the plunger back slowly (Figure E). </p>
<p>4. Disconnect the syringe, attach a suitable needle, and
                                    inject intravenously as instructed. If a patient is to receive
                                    more than one ADVATE-BAXJECT III system or a combination of an
                                    ADVATE-BAXJECT II and an ADVATE-BAXJECT III system, the contents
                                    may be drawn into the same syringe.</p>
<p>5. Administer ADVATE over a period of ≤5 minutes (maximum
                                    infusion rate 10 mL/min). Determine the pulse rate before and
                                    during administration of ADVATE. Should a significant increase
                                    in pulse rate occur, reducing the rate of administration or
                                    temporarily halting the injection usually allows the symptoms to
                                    disappear promptly.</p>
<table width="100%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center"><p class="First"><span class="Bold">Figure D</span></p></td>
<td class="Rrule Toprule" align="center"><p class="First"><span class="Bold">Figure E</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center">
<a name="id1672"></a><img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-04.jpg">
</td>
<td class="Botrule Rrule" align="center">
<a name="id1675"></a><img alt="Figure E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-05.jpg">
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_c1b8b04c-b2ed-4905-8805-a10ce9302281"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">ADVATE is available as a lyophilized powder in single-use vials
                            containing nominally 250, 500, 1000, 1500, 2000, 3000, or 4000
                            International Units (IU, unit). The 250-1500 IU strengths come with 2 mL
                            Sterile Water for Injection (sWFI); the 2000-4000 IU strengths come with
                            5 mL of sWFI. </p>
<p>Each ADVATE is labeled on the housing with the recombinant
                            antihemophilic factor (rAHF) activity expressed in IU per system. This
                            potency assignment employs a factor VIII concentrate standard that is
                            referenced to a WHO (World Health Organization) international standard
                            for factor VIII concentrates and is evaluated by appropriate methodology
                            to ensure accuracy of the results.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_6627a0bb-28ba-4b1d-84a9-607923dd9c7a"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">ADVATE is contraindicated in patients who have life-threatening
                            <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, to mouse or hamster
                            protein or other constituents of the product (mannitol, trehalose,
                            sodium chloride, histidine, Tris, calcium chloride, polysorbate 80,
                            and/or glutathione). </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_586165da-e2c1-48a8-a8be-da97e2a9e58f"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f7f1cb36-7d78-4c97-9813-858934d1b06f"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Allergic-type <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including
                                    <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, have been reported with ADVATE. Symptoms include
                                    <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">facial swelling</span>,
                                    <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. </p>
<p>ADVATE contains trace amounts of mouse <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin G</span>
                                    (MuIgG) ≤0.1 ng/IU ADVATE, and hamster proteins ≤1.5 ng/IU
                                    ADVATE. Patients treated with this product may develop
                                    <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to these non-human mammalian
                                    proteins.</p>
<p>Discontinue ADVATE if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> symptoms occur and
                                    administer appropriate emergency treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1cd0e06c-9c77-4566-9264-842e8c0edaaa"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Neutralizing Antibodies</h2>
<p class="First">Neutralizing antibodies (inhibitors) have been reported
                                    following administration of ADVATE predominantly in previously
                                    untreated patients (PUPs) and previously minimally treated
                                    patients (MTPs). Monitor all patients for the development of
                                    factor VIII inhibitors by appropriate clinical observation and
                                    laboratory testing. If expected plasma factor VIII activity
                                    levels are not attained, or if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is not controlled with
                                    an expected dose, perform an assay that measures factor VIII
                                    inhibitor concentration. [see <span class="Italics">Warnings and Precautions </span>(<a href="#ID_04567f29-97ba-479b-821b-2a451cdb1e77">5.3</a>)]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_04567f29-97ba-479b-821b-2a451cdb1e77"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Monitoring Laboratory Tests</h2>
<dl>
<dt>•</dt>
<dd>Monitor plasma factor VIII activity
                                        levels by the one-stage clotting assay to confirm the
                                        adequate factor VIII levels have been achieved and
                                        maintained when clinically indicated. [see<span class="Italics"> Dosage and Administration
                                            </span>(<a href="#ID_c3304267-c6d5-4223-8378-1d9bcdd6dfec">2.1</a>)]</dd>
<dt>•</dt>
<dd>Monitor for development of factor VIII
                                        inhibitors. Perform the Bethesda assay to determine if
                                        factor VIII inhibitor is present. If expected factor VIII
                                        activity plasma levels are not attained, or if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is
                                        not controlled with the expected dose of ADVATE, use
                                        Bethesda Units (BU) to titer inhibitors.<dl>
<dt>o</dt>
<dd>If the inhibitor titer is less
                                                than 10 BU per mL, the administration of additional
                                                antihemophilic factor concentrate may neutralize the
                                                inhibitor and may permit an appropriate hemostatic
                                                response.</dd>
<dt>o</dt>
<dd>If the inhibitor titer is
                                                above 10 BU per mL, adequate hemostasis may not be
                                                achieved. The inhibitor titer may rise following
                                                ADVATE infusion as a result of an anamnestic
                                                response to factor VIII. The treatment or prevention
                                                of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in such patients requires the use of
                                                alternative therapeutic approaches and
                                                agents.</dd>
</dl>
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_ff0548ed-6d9a-4af1-b3f1-5bcdede187ce"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Serious adverse reactions seen with ADVATE are <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>
                            reactions, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, and the development of high-titer
                            inhibitors necessitating alternative treatments to factor
                            VIII.</p>
<p>The most common adverse reactions observed in clinical trials
                            (frequency greater than 5% of subjects) were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>,
                            and <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, upper respiratory tract
                            <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="444130" conceptname="Injury of foot">limb injury</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b8d83340-b1be-4416-84a9-946a405ec874"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely
                                    varying conditions, adverse reaction rates observed in the
                                    clinical trials of a drug cannot be directly compared to rates
                                    in clinical trials of another drug and may not reflect the rates
                                    observed in clinical practice.</p>
<p>ADVATE has been evaluated in eleven clinical trials in
                                    previously treated patients (PTPs) and one trial in previously
                                    untreated patients (PUPs) with severe to moderately severe
                                    <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> (factor VIII ≤2% of normal). A total of 418
                                    subjects have been treated with ADVATE as of January 2012. Total
                                    exposure to ADVATE was 63,188 infusions. The median duration of
                                    participation per subject was 397 (min-max: 2 −1620) days and
                                    the median number of exposure days to ADVATE per subject was 97
                                    (min-max: −709).</p>
<p>The summary of adverse reactions with a frequency &gt;5%
                                    are shown in Table 3 below. </p>
<p><br>No subject was withdrawn from a clinical trial due
                                    to an adverse reaction.</p>
<a name="_RefID027ABE9D79F74E57BDD273995CEAC572"></a><table width="100%">
<caption><span>Table 3 Summary of Adverse Reactions (ARs)<span class="Sup">1
                                        </span>with a Frequency Greater than 5% in 418 Subjects </span></caption>
<col width="37%">
<col width="22%">
<col width="12%">
<col width="13%">
<col width="12%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>MedDRA
                                                  version 8.1 was used.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">MedDRA</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><span class="Bold"> System Organ
                                                  Class</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">MedDRA Preferred
                                                  Term</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Number of Adverse
                                                  Reactions</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Number of
                                                  Subjects</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Percent of
                                                  Subjects</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">General Disorders And Administration Site
                                                  Conditions</p></td>
<td class="Botrule Lrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">110</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">66</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">16</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></p></td>
<td class="Botrule Lrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">114</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">56</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">13</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Respiratory, Thoracic And Mediastinal
                                                  Disorders</p></td>
<td class="Botrule Lrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">86</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">54</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">13</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> And <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></p></td>
<td class="Botrule Lrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">72</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">49</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">12</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Musculoskeletal And Connective Tissue
                                                  Disorders</p></td>
<td class="Botrule Lrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">49</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">32</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></p></td>
<td class="Botrule Lrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">41</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">31</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">7</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> And <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></p></td>
<td class="Botrule Lrule" valign="middle"><p class="First">Upper Respiratory Tract
                                                  <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">35</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">29</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">7</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> And Procedural
                                                  Complications</p></td>
<td class="Botrule Lrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="444130" conceptname="Injury of foot">Limb Injury</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">56</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">25</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Respiratory, Thoracic And Mediastinal
                                                  Disorders</p></td>
<td class="Botrule Lrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal Congestion</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">32</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">25</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></p></td>
<td class="Botrule Lrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">29</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">24</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> And Procedural
                                                  Complications</p></td>
<td class="Botrule Lrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">Procedural Pain</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">26</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Respiratory, Thoracic And Mediastinal
                                                  Disorders</p></td>
<td class="Botrule Lrule" valign="middle"><p class="First">Oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">25</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> And <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></p></td>
<td class="Botrule Lrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">Ear Infection</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">30</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics"> Immunogenicity </span></p>
<p>The development of factor VIII inhibitors with the use of
                                    ADVATE was evaluated in clinical trials with pediatric PTPs
                                    (&lt;6 years of age with ≥50 factor VIII exposures) and PTPs
                                        (<span class="Underline">&gt;</span>10 years of
                                    age with ≥150 factor VIII exposures). Of 276 subjects who were
                                    treated with ADVATE for at least 10 exposure days or on study
                                    for a minimum of 120 days, 1 adult developed a low-titer
                                    inhibitor (2 BU in the Bethesda assay) after 26 exposure days.
                                    Eight weeks later, the inhibitor was no longer detectable, and
                                        <span class="Italics">in vivo</span> recovery was
                                    normal at 1 and 3 hours after infusion of another marketed
                                    recombinant factor VIII concentrate. This event results in a
                                    factor VIII inhibitor frequency in PTPs of 0.4% (95% CI of 0.01
                                    and 2% for the risk of any factor VIII inhibitor
                                        development).<span class="Sup">3</span> No factor VIII inhibitors were
                                    detected in the 53 treated pediatric PTPs. </p>
<p>In clinical trials that enrolled previously untreated
                                    subjects (defined as having had up to 3 exposures to a factor
                                    VIII product at the time of enrollment) , 16 (29.1%) of 55
                                    subjects who received ADVATE developed inhibitors to factor
                                    VIII. Seven subjects developed high titer (&gt;5 BU) and nine
                                    subjects developed low-titer inhibitors. Inhibitors were
                                    detected at a median of 13 exposure days (min-max: 6 −26
                                    exposure days) to the product.</p>
<p>Immunogenicity also was evaluated by measuring the
                                    development of antibodies to heterologous proteins. When
                                    assessed for anti-Chinese hamster ovary (CHO) cell protein
                                    antibodies, of 229 treated subjects, 3 showed an upward trend in
                                    antibody titer over time and 10 showed repeated but transient
                                    elevations of antibodies. When assessed for muIgG protein
                                    antibodies, of the 229 treated subjects, 10 showed an upward
                                    trend in anti-muIgG antibody titer over time and 2 showed
                                    repeated but transient elevations of antibodies. Four subjects
                                    who demonstrated antibody elevations to CHO cell or muIgG
                                    proteins, reported isolated events of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>,
                                    and slightly elevated eosinophil counts. All of these subjects
                                    had numerous repeat exposures to the product without recurrence
                                    of the events and a causal relationship between the antibody
                                    findings and these clinical events has not been established. </p>
<p>When assessed for the presence of anti-human von
                                    Willebrand Factor (VWF) antibodies, of the 228 treated subjects,
                                    none displayed laboratory evidence indicative of a positive
                                    serologic response.</p>
<p><br>The detection of antibody formation is highly
                                    dependent on the sensitivity and specificity of the assay.
                                    Additionally, the observed incidence of antibody (including
                                    neutralizing antibody) positivity in an assay may be influenced
                                    by several factors including assay methodology, sample handling,
                                    timing of sample collection, concomitant medications, and
                                    underlying disease. For these reasons, comparison of the
                                    incidence of antibodies to ADVATE with the incidence of
                                    antibodies to other products may be misleading.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_aacefbb4-fee9-4230-878c-b45b8ba20024"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified
                                    during post-approval use of ADVATE. Because these reactions are
                                    reported voluntarily from a population of uncertain size, it is
                                    not always possible to reliably estimate their frequency or
                                    establish a causal relationship to drug exposure.</p>
<p>Table 4 represents the most frequently reported
                                    post-marketing adverse reactions as MedDRA Preferred
                                    Terms.</p>
<a name="_RefIDE247EAC091A54537A2429462F33034C5"></a><table width="100%">
<caption><span>Table 4 Post-Marketing Experience </span></caption>
<col width="56%">
<col width="44%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>These
                                                  reactions have been manifested by <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>,
                                                  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, face <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>,
                                                  <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and/or
                                                  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Organ System [MedDRA
                                                  Primary SOC]</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Preferred Term</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span></p></td>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reaction</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a><br><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span><a href="#footnote-2" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Blood and lymphatic system
                                                  disorders</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Factor VIII inhibition </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">General disorders and administration site
                                                  conditions</p></td>
<td class="Botrule Lrule Rrule">
<p class="First"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span></p>
<p><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></p>
<p><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>/<span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></p>
<p><span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Chest discomfort</span>/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
<p>Decreased therapeutic effect</p>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_6a099a17-2328-4a70-8d19-5ab6c8da3980"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_a01ec072-abb5-458d-90e0-eb90f40e1233"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C. Animal reproduction studies have
                                    not been conducted with ADVATE. It is not known whether ADVATE
                                    can cause fetal harm when administered to a pregnant woman or
                                    whether it can affect reproductive capacity. ADVATE should be
                                    given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_f8918e2c-eb97-4a61-8090-43ce3308aade"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human
                                    milk. Because many drugs are excreted in human milk, caution
                                    should be exercised when ADVATE is administered to a nursing
                                    woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_17d6115b-78f3-439a-bf1b-ead359d0ad24"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Pharmacokinetic studies in children have demonstrated
                                    higher clearance, a shorter half-life and lower recovery of
                                    factor VIII compared to adults. [see Clinical Pharmacology
                                    (12.3)] This may be explained by differences in body composition
                                    and should be taken into account when dosing or following factor
                                    VIII levels in the pediatric population.<span class="Sup">4</span> Because
                                    clearance (based on per kg body weight) has been demonstrated to
                                    be higher in the pediatric population, dose adjustment or more
                                    frequent dosing based on per kg body weight may be needed in
                                    this population. [see Clinical Pharmacology (12.3)] In the
                                    ADVATE routine prophylaxis clinical trial, 3 children aged 7 to
                                    &lt;12 and 4 adolescents aged 12 to &lt; 16 were included in the
                                    per-protocol analysis. The reductions in annualized <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
                                    rate per subject per year during any prophylaxis regimen as
                                    compared to during on-demand therapy were similar among
                                    children, adolescents, and adults. [see Clinical Studies
                                    (14)].</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_b3878cab-f554-42e5-87fa-468227f86730"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical trials of ADVATE did not include sufficient
                                    numbers of subjects aged 65 and over to determine whether they
                                    respond differently compared to younger subjects. Individualize
                                    dose selection for geriatric patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_a6cf8e6a-8606-4c81-b76d-532e046ffb6b"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">ADVATE [Antihemophilic Factor (Recombinant)] is a purified
                            glycoprotein consisting of 2,332 amino acids that is synthesized by a
                            genetically engineered Chinese hamster ovary (CHO) cell line but does
                            not contain plasma or albumin. The CHO cell line employed in the
                            production of ADVATE is derived from that used in the biosynthesis of
                            RECOMBINATE [Antihemophilic Factor (Recombinant)]. ADVATE has been shown
                            to be comparable to RECOMBINATE with respect to its biochemical and
                            physicochemical properties, as well as its non-clinical <span class="Italics">in vivo</span> pharmacology. </p>
<p>In culture, the CHO cell line expresses the recombinant
                            antihemophilic factor (rAHF) into the cell culture medium. The rAHF is
                            purified from the culture medium using a series of chromatography
                            columns. The purification process includes an immunoaffinity
                            chromatography step in which a monoclonal antibody directed against
                            factor VIII is employed to selectively isolate the rAHF from the medium.
                            The cell culture and purification processes used in the manufacture of
                            ADVATE employ no additives of human or animal origin. The production
                            process includes a dedicated, viral inactivation solvent-detergent
                            treatment step. The rAHF synthesized by the CHO cells has the same
                            biological effects on clotting as human antihemophilic factor (hAHF).
                            Structurally the recombinant protein has a similar combination of
                            heterogeneous heavy and light chains as found in AHF
                            (Human).</p>
<p>ADVATE is formulated as a sterile, non-pyrogenic, white to
                            off-white powder for intravenous injection. ADVATE in a single-use vial
                            contains nominally 250, 500, 1000, 1500, 2000, 3000, or 4000
                            International Units (IU). The product contains the following stabilizers
                            and excipients: mannitol, trehalose, sodium chloride, histidine, Tris,
                            calcium chloride, polysorbate 80, and glutathione. Von Willebrand factor
                            (VWF) is co-expressed with factor VIII and helps to stabilize it in
                            culture. The final product contains no more than 2 ng VWF/IU rAHF, which
                            will not have any clinically relevant effect in patients with von
                            Willebrand disease. </p>
<p>The product contains no preservative. When reconstituted with the
                            provided Sterile Water for Injection, USP, the final solution contains
                            the following stabilizers and excipients in targeted
                            amounts:</p>
<a name="_RefID230B4A0295404C35ACA665D5252731A7"></a><table width="100%">
<caption><span>Table 5 Approximate Concentration of Stabilizer and Excipient
                                after Reconstitution </span></caption>
<col width="26%">
<col width="30%">
<col width="27%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Stabilizer and
                                                Excipient</span></p></td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">2 mL Reconstitution</span></p>
<p><span class="Bold">(for 250, 500, 1000, 1500
                                                IU)</span></p>
<p><span class="Bold">Target</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">5 mL Reconstitution</span></p>
<p><span class="Bold">(for 2000, 3000, 4000
                                                IU)</span></p>
<p><span class="Bold">Target</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">Tris (hydroxymethyl)<br>aminomethane</p></td>
<td class="Botrule Lrule" align="center"><p class="First">25 mM</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 mM</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">Calcium Chloride </p></td>
<td class="Botrule Lrule" align="center"><p class="First">4.2 mM</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.7 mM</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">Mannitol</p></td>
<td class="Botrule Lrule" align="center"><p class="First">8 % (w/v)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.2% (w/v)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">Sodium Chloride</p></td>
<td class="Botrule Lrule" align="center"><p class="First">225 mM</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">90mM</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">α, α-Trehalose</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2% (w/v)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.8% (w/v)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">Histidine</p></td>
<td class="Botrule Lrule" align="center"><p class="First">25 mM</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 mM</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">Glutathione (Reduced)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.2 mg/mL</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.08 mg/mL</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">Polysorbate 80</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.025% (w/v)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.01% (w/v)</p></td>
</tr>
</tbody>
</table>
<p>Each ADVATE housing is labeled with the rAHF activity expressed
                            in international units. Biological potency is determined by an <span class="Italics">in vitro</span> assay, which employs a factor
                            VIII concentrate standard that is referenced to a WHO international
                            standard for factor VIII concentrates. One international unit, as
                            defined by the WHO standard for blood coagulation factor VIII, human, is
                            approximately equal to the level of factor VIII activity found in 1 mL
                            of fresh pooled human plasma. The specific activity of ADVATE is 4000 to
                            10000 International Units per milligram of protein.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_96a72988-c429-4190-acdd-e44139e1afb5"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_db8cda6c-2a77-42e8-ab87-4eba81bb50bf"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">ADVATE temporarily replaces the missing coagulation
                                    factor VIII that is needed for effective hemostasis.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_16f66af6-dd05-4c0b-ae0f-49438f3ba650"></a><a name="section-9.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span> (aPTT) is
                                    prolonged in patients with <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span>. Determination of aPTT is
                                    a conventional <span class="Italics">in vitro</span>
                                    assay for biological activity of factor VIII. Treatment with
                                    ADVATE normalizes the aPTT over the effective dosing
                                    period.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_b259dfd3-5136-4800-b623-ead63ae5b430"></a><a name="section-9.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">A randomized, crossover pharmacokinetic trial of ADVATE
                                    (test) and RECOMBINATE [Antihemophilic Factor (Recombinant)]
                                    (reference) was conducted in 56 non-<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> subjects. The
                                    subjects received either of the products as an IV infusion (50 ±
                                    5 IU/kg body weight) and there was a washout period of 72 hours
                                    to 4 weeks between the two infusions. The pharmacokinetic
                                    parameters were calculated from factor VIII activity
                                    measurements in blood samples obtained up to 48 hours following
                                    each infusion.<span class="Sup">3</span> The per-protocol analysis included 30
                                    patients (20 adults and 10 children). Pharmacokinetic parameters
                                    for the 20 adults for each trial are presented in Table
                                    6.</p>
<a name="_RefID26F615C299DF43DCA396F5C82A7834E4"></a><table width="100%">
<caption><span>Table 6 Pharmacokinetic Parameters (Mean ± SD) for
                                        ADVATE and RECOMBINATE (N=20 Adult Subjects Age &gt;16
                                        years) </span></caption>
<col width="39%">
<col width="28%">
<col width="28%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold"> RECOMBINATE </span></p>
<p><span class="Bold"> (n=20) </span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">ADVATE</span></p>
<p><span class="Bold">(n=20) </span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">C<span class="Sub">max</span> (IU/dL)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">136 ± 29</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">128 ± 28</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">MRT (hrs)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">14.7 ± 3.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15.8 ± 5.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">V<span class="Sub">ss</span> (dL/kg)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.4 ± 0.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.4 ± 0.1</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">CL (dL/hrs/kg)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3 ± 1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3 ± 1</p></td>
</tr>
</tbody>
</table>
<p>The 90% confidence intervals for the ratios of the mean
                                        AUC<span class="Sub">(0-48h)</span> and <span class="Italics">in
                                        vivo</span> recovery values for the test and control
                                    products were within the pre-established limits of 0.80 and
                                    1.25. In addition, <span class="Italics">in
                                        vivo</span> recoveries at the onset of treatment and
                                    after 75 exposure days were compared for 62 subjects. Results of
                                    this analysis indicated no significant change in the <span class="Italics">in vivo</span> recovery at the onset
                                    of treatment and after ≥ 75 exposure days.</p>
<p>In an analysis of data from 58 subjects with 65 surgical
                                    procedures in the perioperative management trial, the target
                                    factor VIII level was met or exceeded in all cases following a
                                    single loading dose ranging from 29 to 104 IU/kg. </p>
<p>Pharmacokinetic parameters calculated from 98 subjects
                                    less than 16 years of age (intent-to-treat analysis) are
                                    available for 7 infants (1 month to less than 2 years), 32
                                    children (2 to less than 5 years), 24 older children (5 to less
                                    than 12 years), and 35 adolescents (12 to less than 16 years),
                                    as shown in Table 7. The mean clearance (based on body weight)
                                    of ADVATE in infants, children, older children, and adolescents
                                    was higher than adults (3.6 mL/kg*hr). The mean half-life of
                                    ADVATE in infants, children, older children, and adolescents was
                                    lower than adults (12 hours). The extent to which these
                                    differences may be clinically significant is not
                                    known.</p>
<a name="_RefID7269AD8A7B274CECB13C0700A6BA3444"></a><table width="100%">
<caption><span>Table 7 Pharmacokinetic Parameters (Mean ± SD) of
                                        ADVATE by Age Group &lt;16 Years (N=98; Intent-to-Treat PK
                                        Analysis Set) </span></caption>
<col width="23%">
<col width="20%">
<col width="18%">
<col width="18%">
<col width="21%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Parameters</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Infants<br>(N=7)<br>(1
                                                  month to &lt;2 yrs)</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Children<br>(N=32)<br>(2 to &lt;5
                                                  yrs)</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Older
                                                  Children<br>(N=24)<br>(5 to &lt; 12
                                                  yrs)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Adolescents<br>(N=35)<br>(12 to &lt; 16
                                                  years)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule">
<p class="First">AUC<span class="Sub">0-inf</span></p>
<p> (IU*hr/dL)</p>
</td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">1240 ± 330</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">1164 ± 424</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">1396 ± 506</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1300 ± 469</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Incremental Recovery at
                                                  C<span class="Sub">max</span><span class="Sup"> a</span> (IU/dL per
                                                  IU/kg)</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">2.1 ± 0.5</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">1.8 ± 0.4</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">2.1 ± 0.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">2.1 ± 0.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Half-Life (hr)</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">8.7 ± 1.4</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">9.5 ± 1.8</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">11.2 ± 3.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">12.0 ± 2.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Maximum Plasma Concentration Post
                                                  Infusion (IU/dL)</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">104 ± 27</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">91 ± 19</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">105 ± 34</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">103 ± 25</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Mean Residence Time (hr)</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">10.4 ± 2.5</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">11.8 ± 2.8</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">14.3 ± 4.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">14.9 ± 4.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Volume of Distribution at Steady State
                                                  (dL/kg)</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">0.4 ± 0.1</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">0.5 ± 0.1</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">0.6 ± 0.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.6 ± 0.1</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Clearance (mL/kg*hr)</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">4.3 ± 1.0</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">4.8 ± 1.5</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">4.1 ± 1.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4.2 ± 1.2</p></td>
</tr>
</tbody>
</table>
<p>In a crossover pharmacokinetic trial of rAHF-PFM
                                    reconstituted in 2 mL versus 5 mL Sterile Water for Injection,
                                    USP (sWFI) in previously treated severe <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> adult and
                                    adolescent patients, the AUCs of the two formulations were
                                    comparable and the 90% confidence interval ranged from 90.4 to
                                    102.6, indicating that the two formulations are
                                    pharmacokinetically equivalent.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_1bf5b26d-9862-450f-b63a-18f001a3b487"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_11d5eeff-51d6-4f6b-b3f9-f81dfa3d99e1"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No studies have been conducted with the active ingredient
                                    in ADVATE to assess its mutagenic or carcinogenic
                                    potential.</p>
<p>RECOMBINATE was tested for mutagenicity at doses
                                    considerably exceeding plasma concentrations <span class="Italics">in vitro</span>, and at doses up to
                                    ten times the expected maximal clinical dose <span class="Italics">in vivo</span>. At that
                                    concentration, it did not cause reverse mutations, chromosomal
                                    aberrations, or an increase in micronuclei formation in bone
                                    marrow polychromatic erythrocytes. Studies in animals have not
                                    been performed to evaluate carcinogenic potential.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="ID_53802845-7e4b-4a3c-b844-119cf9e81c68"></a><a name="section-10.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Single doses up to 4,750 IU/kg did not demonstrate any
                                    acute or toxic effect for ADVATE in laboratory animals (rat and
                                    rabbit).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_eda5d16b-9d33-4953-9d03-04d0ff4350b5"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First"><span class="Italics">Original Safety and Efficacy
                                Study</span></p>
<p>A safety and efficacy trial evaluated the pharmacokinetics
                            (double-blinded, randomized, cross-over), safety, immunogenicity, and
                            hemostatic efficacy (open-label) of ADVATE in 111 subjects. The trial
                            was conducted in the US and Europe with 103 Caucasian, 7 Black, and 1
                            Asian previously treated subjects (PTPs with ≥ 150 exposure days)
                            diagnosed with moderate to severe <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> (FVIII level ≤ 2% of
                            normal) who were ≥10 years of age (20 were 10 to &lt;13, 22 were 13 to
                            &lt;16, and 69 were 16 years and older). Subjects with a history of, or
                            a detectable FVIII inhibitor were excluded. </p>
<p>Subjects self-administered ADVATE for routine prophylaxis (≥25
                            IU/kg body weight 3-4 times per week) and for the on-demand treatment of
                            <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes. A global assessment of efficacy was rendered by the
                            subject (for home treatment) or study site investigator (for treatment
                            under medical supervision) using a scale of excellent, good, fair, or
                            none, based on the quality of hemostasis achieved with ADVATE for the
                            treatment of each new <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episode. </p>
<p>A total of 510 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes were reported, with a mean (±
                            SD) of 6.1 ± 8.2 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes per subject. Of these 510 episodes,
                            439 (86%) were rated excellent or good in their response to treatment
                            with ADVATE, 61 (12%) were rated fair, 1 (0.2%) was rated as having no
                            response, and for 9 (2%), the response to treatment was unknown. A total
                            of 411 (81%) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes were managed with a single infusion, 62
                            (12%) required 2 infusions, 15 (3%) required 3 infusions, and 22 (4%)
                            required 4 or more infusions of ADVATE for satisfactory resolution. A
                            total of 162 (32%) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes occurred spontaneously, 228 (45%)
                            were the result of antecedent <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, and for 120 (24%) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
                            episodes, the etiology was unknown.<span class="Sup">3</span></p>
<p>The rate of new <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes during the 75-exposure-day
                            <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> regimen was calculated as a function of the etiology of
                            <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes for 107 evaluable subjects (n = 274 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
                                episodes).<span class="Sup">3</span> These rates are presented in Table 8. The
                            overall rate of new <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes in the prophylaxis study was 0.52
                            ± 0.71.</p>
<a name="_RefID1BC85BCD7BD2412C8A8D63EB64E5015B"></a><table width="100%">
<caption><span>Table 8 Rate of New <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Episodes During Prophylaxis </span></caption>
<col width="28%">
<col width="54%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Types of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Episode
                                            </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Mean (± SD) New <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>
                                                Episodes/Subject/Month</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">Spontaneous</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.34 ± 0.49</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">Post-traumatic</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.39 ± 0.46</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">Unknown/Indeterminate</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.33 ± 0.34</p></td>
</tr>
</tbody>
</table>
<p>The pharmacokinetic properties of ADVATE were investigated at the
                            beginning of treatment in a multicenter trial of previously treated
                            subjects and at the end of treatment in a subset of subjects (N=34) who
                            had completed at least 75 exposure days of treatment with ADVATE.
                            [Clinical Pharmacology (12.3)].</p>
<p><span class="Italics">Continuation Study</span></p>
<p>Additional (open-label) safety and efficacy data were collected
                            on 82 subjects who continued with treatment following participation in
                            the original safety and efficacy study. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> episodes were treated
                            with ADVATE and the outcome of treatment was rated as excellent, good,
                            fair, or none, based on the quality of hemostasis achieved. Final
                            analysis of efficacy was conducted for 81 subjects who self-administered
                            ADVATE on a routine <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> regimen for a minimum period of 75
                            exposure days. </p>
<p>A total of 837 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes occurred in 70 of the 81
                            subjects. The other 11 subjects experienced no <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes. The
                            response to treatment with ADVATE was rated as excellent or good for
                            80.4% of all <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes. Most (88%) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes required
                            only 1 or 2 infusions to obtain hemostasis. Among the 837 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
                            episodes, 2 (0.3%) did not require treatment (0 infusions), 521 (62.2%)
                            required 1 infusion, 216 (25.8%) required 2 infusions, 23 (2.7%)
                            required 3 infusions, and 75 (9.0%) required 4 or more infusions. By
                            etiology, 45.3% of these <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events were secondary to <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> and
                            27.7% occurred spontaneously; the other 27% had an undetermined
                            etiology.</p>
<p><span class="Italics">In vivo</span> recoveries at the
                            onset of treatment and after 75 exposure days were compared for 62
                            subjects and there were no significant differences.</p>
<p><span class="Italics">Perioperative Management Study </span></p>
<p>The safety and efficacy of ADVATE for perioperative management
                            was investigated in 59 subjects with severe or moderately severe
                            <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> (factor VIII ≤ 2%). They were between the ages of 7 to 65
                            years of age (3 were 7 to &lt;13, 6 were 13 to &lt; 16, and 50 were ≥
                            16). Fifty-five were Caucasian, 3 were Black, and 1 was Asian. One
                            subject elected not to undergo the planned surgery. Thus, 58 subjects
                            underwent 65 surgical procedures, among which, 6 subjects underwent more
                            than 1 procedure each. One subject withdrew during the postoperative
                            period; thus, 57 subjects completed the study. Of the 65 procedures, 22
                            in 22 subjects were classified as major, 35 in 28 subjects were
                            classified as minor, and 8 in 8 subjects were dental. (See Table 2 for
                            definitions of major and minor)</p>
<p>Prior to surgery, subjects received a pre-operative loading dose
                            aimed at increasing the plasma factor VIII level to 60% to 100% of
                            normal for dental procedures or 80% to 120% of normal for all other
                            surgical procedures. During the surgery, subjects received replacement
                            therapy by either bolus (47 procedures) or continuous infusion (18
                            procedures). For continuous infusion, the initial rate was 4 IU/kg/hr
                            for subjects &gt;12 years of age and 5 IU/kg/hr for subjects 5 to 12
                            years of age. After discharge, subjects continued to receive ADVATE for
                            control of hemostasis as prescribed by the investigator for up to 6
                            weeks for major orthopedic procedures and up to 2 weeks for all other
                            procedures. </p>
<p>Intraoperative efficacy was rated as excellent or good (Excellent
                            intraoperative blood loss was less than expected for the type of
                            procedure performed; Good intraoperative blood loss was as expected for
                            the type of procedure performed.) for 61 (93.9%) of the 65 procedures;
                            the rating was not done for 3 procedures and unknown for 1 procedure.
                            Postoperative efficacy was rated as excellent or good for 62 (95.4%) of
                            the 65 procedures; the rating was unknown for 2 procedures and not done
                            for 1 procedure. Of the 24 procedures requiring surgical drains,
                            efficacy assessments at the time of drain removal were rated as
                            excellent or good for 20 (83.3%) procedures and fair (Fair
                            intraoperative blood loss was more than expected for the type of
                            procedure performed) for 2 (8.3%) procedures; the rating was unknown for
                            1 procedure and not done for 1 procedure. Both procedures requiring
                            surgical drains with fair ratings were major orthopedic
                            surgeries.</p>
<p><span class="Italics">Routine Prophylaxis Study</span></p>
<p>In a multicenter, open-label, prospective, randomized, controlled
                            postmarketing clinical trial of ADVATE use in two <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment
                            regimens compared to that of on-demand treatment, 53 PTPs with severe to
                            moderately severe <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> (FVIII level <span class="Underline">&lt;</span> 2 IU/dL) were analyzed in the
                            per-protocol group. Subjects were initially treated for 6 months of
                            on-demand therapy and then randomized to 12 months of either a standard
                            prophylaxis regimen (20-40 IU/kg every 48 hours) or PK-driven
                            prophylaxis regimen (20-80 IU/kg every 72 hours). All subjects had a
                            history of at least 8 joint <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes per year upon entering the
                            trial. Each subject in the per-protocol group was adherent to &gt; 90%
                            of the prescribed number of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> infusions; no subject in the
                            trial surpassed the upper boundary of 110% of the prescribed number of
                            <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> infusions.</p>
<p>The equation used to determine the weight-adjusted dose of the
                            product used in the PK-driven prophylaxis arm, as calculated from the
                            individual subject’s incremental recovery and half-life values to
                            achieve a trough level of ≥ 1 IU/dL at the inter-dosing interval of 72
                            hours is defined as follows:</p>
<dl>
<dt> </dt>
<dd>D<span class="Sub">i</span> =
                                    (2)<span class="Sup">72/t</span><span class="Sub">i</span><span class="Sup"></span>/ r<span class="Sub">i</span> (i is
                                the subject)</dd>
<dt> </dt>
<dd>D = target FVIII dose (IU/kg) that ensures
                                that a trough level of ≥1 IU/dL is achieved after 72 hours</dd>
<dt> </dt>
<dd>r = FVIII incremental recovery (IU/dL / IU/kg)
                                as determined by the subject’s PK analysis</dd>
<dt> </dt>
<dd>t = FVIII half-life (hrs) as determined by the
                                subject’s PK analysis</dd>
</dl>
<p>The median annual bleed rate during the on-demand therapy period
                            was 44 bleeds per subject per year compared to 1 bleed per subject per
                            year while on either prophylaxis regimen, which was a statistically
                            significant difference (p&lt;0.0001). Twenty-two of 53 (42%) subjects
                            experienced no <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes while on prophylaxis for one year.
                            While there was no statistically significant difference in <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
                            frequency observed between the two prophylaxis regimens studied, the
                            trial was not powered to demonstrate equivalence in <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> rate
                            between the two prophylaxis arms.</p>
<table width="100%">
<caption><span>Table 9 Annual Bleed Rate of Prophylaxis Compared to On-Demand
                                Treatment</span></caption>
<col width="23%">
<col width="15%">
<col width="17%">
<col width="19%">
<col width="26%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Clinical Parameters</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="middle"><dl>
<dt> </dt>
<dd><span class="Bold">On-Demand<br>(n=53)</span></dd>
</dl></td>
<td class="Botrule Lrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Standard
                                                Prophylaxis<br>(n=30)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><dl>
<dt> </dt>
<dd><span class="Bold">PK-Driven
                                                  Prophylaxis<br>(n=23)</span></dd>
</dl></td>
<td class="Botrule Lrule Toprule" align="center"><dl>
<dt> </dt>
<dd><span class="Bold"> Either Standard or
                                                  PK-Driven Prophylaxis<br>(n=53)</span></dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Median (IQR)<span class="Sup">1</span> Annual Bleed
                                            Rate(ABR)</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><dl>
<dt> </dt>
<dd>44.0 (20.8)</dd>
</dl></td>
<td class="Botrule Lrule" align="center" valign="middle"><dl>
<dt> </dt>
<dd>1.0 (2.1)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt> </dt>
<dd>1.0 (4.1)</dd>
</dl></td>
<td class="Botrule Lrule" valign="middle"><dl>
<dt> </dt>
<dd>1.0 (4.1)</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Median (IQR)<span class="Sup"> 1</span> Joint ABR </p></td>
<td class="Botrule Lrule" align="center" valign="middle"><dl>
<dt> </dt>
<dd>38.7 (24.8)</dd>
</dl></td>
<td class="Botrule Lrule" align="center" valign="middle"><dl>
<dt> </dt>
<dd>0.5 (2.0)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt> </dt>
<dd>1.0 (4.1)</dd>
</dl></td>
<td class="Botrule Lrule" valign="middle"><dl>
<dt> </dt>
<dd>1.0 (2.1)</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Median (IQR)<span class="Sup"> 1</span> Non-Joint
                                                ABR<span class="Sup">1</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><dl>
<dt> </dt>
<dd>4.0 (11.9)</dd>
</dl></td>
<td class="Botrule Lrule" align="center" valign="middle"><dl>
<dt> </dt>
<dd>0.0 (0.0)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt> </dt>
<dd>0.0 (0.0)</dd>
</dl></td>
<td class="Botrule Lrule" valign="middle"><dl>
<dt> </dt>
<dd>0.0 (0.0)</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Median (IQR)<span class="Sup">1 </span>Spontaneous
                                            ABR</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><dl>
<dt> </dt>
<dd>32.0 (26.8)</dd>
</dl></td>
<td class="Botrule Lrule" align="center" valign="middle"><dl>
<dt> </dt>
<dd>0.0 (1.9)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt> </dt>
<dd>0.0 (2.0)</dd>
</dl></td>
<td class="Botrule Lrule" valign="middle"><dl>
<dt> </dt>
<dd>0.0 (1.9)</dd>
</dl></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Median (IQR)<span class="Sup">1 </span>Traumatic
                                            ABR</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><dl>
<dt> </dt>
<dd>11.5 (17.2)</dd>
</dl></td>
<td class="Botrule Lrule" align="center" valign="middle"><dl>
<dt> </dt>
<dd>0.0 (1.0)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt> </dt>
<dd>1.0 (1.0)</dd>
</dl></td>
<td class="Botrule Lrule" valign="middle"><dl>
<dt> </dt>
<dd>0.0 (1.0)</dd>
</dl></td>
</tr>
</tbody>
</table>
<p>The annualized bleed rates by age category during on-demand and
                            either standard or PK-driven prophylaxis regimens are shown in Table
                            10.<br></p>
<table width="100%">
<caption><span>Table 10 Annualized Bleed Rate by Age Category and Any
                                Prophylaxis vs On-Demand (Per Protocol)</span></caption>
<col width="19%">
<col width="12%">
<col width="8%">
<col width="20%">
<col width="13%">
<col width="27%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold">Any Prophylaxis</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">On-Demand</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First">Age Category</p></td>
<td class="Botrule Lrule" valign="middle"><p class="First">Number of Subjects</p></td>
<td class="Botrule Lrule" valign="middle"><p class="First">Median</p></td>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Percentage of Subjects With Zero Bleeds
                                        </p></td>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Median</p></td>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Percentage of Subjects With Zero
                                            Bleeds</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First">Children<br>(≥7 to &lt;12 years old)</p></td>
<td class="Botrule Lrule" valign="middle"><p class="First">3</p></td>
<td class="Botrule Lrule" valign="middle"><p class="First">5.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">33%</p></td>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">44.0</p></td>
<td class="Botrule Lrule Rrule" align="center" rowspan="4"><p class="First">All subjects bleed during On-Demand</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First">Adolescents<br>(≥12 to &lt;16 years
                                            old)</p></td>
<td class="Botrule Lrule" valign="middle"><p class="First">4</p></td>
<td class="Botrule Lrule" valign="middle"><p class="First">5.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">25%</p></td>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">58.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First">Adults<br>(≥16 years old and older)</p></td>
<td class="Botrule Lrule" valign="middle"><p class="First">46</p></td>
<td class="Botrule Lrule" valign="middle"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">43%</p></td>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">44.7</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="middle"><p class="First">All Subjects</p></td>
<td class="Botrule Lrule" align="center"><p class="First">53</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">42%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">44.0</p></td>
</tr>
</tbody>
</table>
<p>As a secondary endpoint, the trial assessed all Short Form Health
                            Survey (SF-36v1) domains. The SF-36v1 is a valid and reliable measure of
                            health-related quality of life that is comprised of 8 domains
                            categorized into 2 summary scores (Table 11).</p>
<a name="_RefID0F85E5E6215442ACB34CC45D6F8AC7B6"></a><table width="100%">
<caption><span>Table 11 Mean Change in SF-36v1 Health Domain Scores Between
                                End of On-Demand and End of Prophylaxis Treatment
                                    Regimens<span class="Sup">1</span></span></caption>
<col width="25%">
<col width="15%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First"><span class="Bold">SF-36v1 Health
                                                Domain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Mean Change</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">95% Confidence
                                                Interval</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Physical Functioning (PF)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.89</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(-1.02, 2.81)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Role Physical (RP)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.56</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(0.32, 6.79)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Bodily <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> (BP)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.13</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(1.63, 6.62)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">General Health (GH)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.36</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(-0.72, 3.45)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Physical Component Score</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.56</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(1.56, 5.56)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Vitality (VT)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.21</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(-2.22, 2.63)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Social Functioning (SF)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.72</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(-0.57, 4.00)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Role Emotional (RE)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-1.29</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(-3.78, 1.19)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Mental Health (MH)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-0.20</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(-2.89, 2.49)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Mental Component Score</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-1.22</p></td>
<td class="Botrule Lrule" align="center"><p class="First">(-3.66, 1.23)</p></td>
</tr>
</tbody>
</table>
<p>1. Positive change values are in the favorable
                            direction.</p>
<p><span class="Italics">Human Factors Usability Study</span></p>
<p>A human factors study was performed with 44 participants to
                            evaluate the usability of the ADVATE in the BAXJECT III reconstitution
                            system. Participants in the study included 15 patients, 16 caregivers,
                            and 13 healthcare providers.</p>
<p>During the study, participants viewed an instructional video then
                            performed the reconstitution steps utilizing the instructions for use
                            (IFU). Objective performance data were collected and evaluated.
                            Participants’ comments from a post-evaluation interview were reviewed
                            for their appropriateness and applicability. As a result, the content of
                            the package insert was revised to clarify the instructions for
                            use.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID_84b35b4a-2eb6-40a0-9c75-37e3615d9a85"></a><a name="section-12"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Fischer K, Collins P, Björkman S, Blanchette
                                V, Oh M, Fritsch S, Schroth P, Spotts G, Ewenstein B. Trends in
                                <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> patterns during prophylaxis for severe haemophilia:
                                observations from a series of prospective clinical trials.
                                Haemophilia 2011 17(3):433-8.</dd>
<dt>2.</dt>
<dd>Collins PW, Blanchette VS, Fischer K,
                                Björkman S, Oh M, Fritsch S, Schroth P, Astermark J, Spotts G,
                                Ewenstein B, The rAHF-PFM Study Group. Break-through <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in
                                relation to predicted factor VIII levels in patients receiving
                                <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment for severe <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">haemophilia A</span>. J Thromb Haemost
                                2009 7(3):413-20.</dd>
<dt>3.</dt>
<dd>Tarantino MD, Collins PW, Hay PW <span class="Italics">et al</span>. Clinical evaluation of an
                                advanced category antihaemophilic factor prepared using a
                                plasma/albumin-free method: pharmacokinetics, efficacy, and safety
                                in previously treated patients with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">haemophilia A</span>. Haemophilia 2004
                                10:428-437.</dd>
<dt>4.</dt>
<dd>Björkman S, Blanchette VS, Fischer K, Oh M,
                                Spotts G, Schroth P, Fritsch S, Patrone L, Ewenstein BM, Collins PW,
                                ADVATE Clinical Program Group. Comparative pharmacokinetics of
                                plasma- and albumin-free recombinant factor VIII in children and
                                adults: the influence of blood sampling schedule on observed
                                age-related differences and implications for dose tailoring. J
                                Thromb Haemost 2010 8(4):730-6.</dd>
<dt>5.</dt>
<dd>Negrier C, Shapiro A, Berntorp E et al.
                                Surgical evaluation of a recombinant factor VIII prepared using a
                                plasma/albumin-free method: efficacy and safety of ADVATE in
                                previously treated patients. Thromb.Haemost 2008100:217-223.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_f36ee19d-2bc2-437b-9f97-a16d66a1d4a2"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Italics">How Supplied</span></p>
<p>ADVATE in a BAXJECT III system is packaged with 2 mL or 5 mL of
                            Sterile Water for Injection, one Terumo Microbore Infusion set (2 mL
                            only), one full prescribing physician insert, and one patient
                            insert.</p>
<p>ADVATE is available in single-dose vials that contain the
                            following nominal product strengths:</p>
<table width="100%">
<col width="19%">
<col width="22%">
<col width="30%">
<col width="30%">
<tbody class="Headless">
<tr class="First Toprule">
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Nominal Strength</span></p></td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Factor VIII </span></p>
<p><span class="Bold">Potency Range</span></p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Carton NDC</span></p>
<p><span class="Bold">(Includes 2 mL sWFI
                                                Diluent)</span></p>
</td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Carton NDC</span></p>
<p><span class="Bold">(Includes 5 mL sWFI
                                                Diluent)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">250 IU</p></td>
<td class="Botrule Lrule"><p class="First">200-400 IU per vial</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0944-3051-02</p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">500 IU</p></td>
<td class="Botrule Lrule"><p class="First">401-800 IU per vial</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0944-3052-02</p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">1000 IU</p></td>
<td class="Botrule Lrule"><p class="First">801-1200 IU per vial</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0944-3053-02</p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">1500 IU</p></td>
<td class="Botrule Lrule"><p class="First">1201-1800 IU per vial</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0944-3054-02</p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">2000 IU</p></td>
<td class="Botrule Lrule"><p class="First">1801-2400 IU per vial</p></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">0944-3045-10</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">3000 IU</p></td>
<td class="Botrule Lrule"><p class="First">2401-3600 IU per vial</p></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">0944-3046-10</p></td>
</tr>
<tr class="Botrule Last">
<td class="Botrule Lrule" align="center"><p class="First">4000 IU</p></td>
<td class="Botrule Lrule"><p class="First">3601-4800 IU per vial</p></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First">0944-3047-10</p></td>
</tr>
</tbody>
</table>
<p>Actual factor VIII activity in International Units is stated on
                            the label of each ADVATE housing or carton.</p>
<p>Not made with natural rubber latex.</p>
<p><span class="Italics">Storage and Handling</span></p>
<dl>
<dt>•</dt>
<dd>Refrigerate ADVATE in powder form at 2° - 8°C
                                (36° - 46°F).</dd>
<dt>•</dt>
<dd>Store at room temperature up to 30°C (86°F)
                                for a period of up to 6 months not to exceed the expiration date. </dd>
<dt>•</dt>
<dd>Record on the carton the date ADVATE is
                                removed from refrigeration.</dd>
<dt>•</dt>
<dd>The product must not be returned to
                                refrigerated temperature.</dd>
<dt>•</dt>
<dd>Do not use beyond the expiration date printed
                                on the ADVATE label or carton. </dd>
<dt>•</dt>
<dd>Do not freeze.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_1796fd97-9e23-44dc-9c0f-9037183daa17"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<dl>
<dt>•</dt>
<dd>Advise the patient to read the FDA-Approved
                                Patient Labeling and Instructions for Use.</dd>
<dt>•</dt>
<dd>Advise patients to report any adverse
                                reactions or problems following ADVATE administration to their
                                physician or healthcare provider.</dd>
<dt>•</dt>
<dd>Allergic-type <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have
                                been reported with ADVATE. Warn patients of the early signs of
                                <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, generalized
                                <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and acute
                                <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>. Advise patients to discontinue use of the
                                product if these symptoms occur and seek immediate emergency
                                treatment. </dd>
<dt>•</dt>
<dd>Inhibitor formation may occur with the
                                treatment of a patient with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>. Advise patients to contact
                                their physician or treatment center if they experience a lack of
                                clinical response to factor VIII replacement therapy, as this may be
                                a manifestation of an inhibitor. </dd>
<dt>•</dt>
<dd>Advise patients to consult with their
                                physicians or healthcare provider prior to travel. While traveling,
                                advise patients to bring an adequate supply of ADVATE based on their
                                current regimen of treatment. </dd>
</dl>
<p class="First">To enroll in the confidential, industry-wide Patient Notification
                            System, call 1-888-873-2838.</p>
<p>Baxter, Advate, Baxject and Recombinate are trademarks of Baxter
                            International Inc. Baxter, Advate and Baxject are registered in the U.S.
                            Patent and Trademark Office.</p>
<p>Patented: see <a href="http://www.baxter.com/productpatents/">www.baxter.com/productpatents/</a></p>
<p><span class="Bold">Baxter Healthcare
                            Corporation</span><br>Westlake Village, CA 91362 USA<br>U.S.
                            License No. 140<br>Printed in USA <a href="http://www.baxter.com/productpatents/">http://www.baxter.com/productpatents/</a></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_be6ebf02-302f-4f02-901c-dc5edf593076"></a><a name="section-15"></a><p></p>
<h1>Patient Package Insert</h1>
<p class="First"><span class="Bold">FDA-Approved Patient Labeling</span></p>
<p><span class="Bold">ADVATE (ad-vate)<br>[Antihemophilic Factor
                                (Recombinant)] </span></p>
<p>This leaflet summarizes important information about ADVATE.
                            Please read it carefully before using this medicine. This information
                            does not take the place of talking with your healthcare provider, and it
                            does not include all of the important information about ADVATE. If you
                            have any questions after reading this, ask your healthcare
                            provider.</p>
<p><span class="Bold">What is the most important information I need
                                to know about ADVATE?</span></p>
<p>Do not attempt to do an infusion to yourself unless you have been
                            taught how by your healthcare provider or <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> center.</p>
<p>You must carefully follow your healthcare provider’s instructions
                            regarding the dose and schedule for infusing ADVATE so that your
                            treatment will work best for you.</p>
<p><span class="Bold">What is ADVATE?</span></p>
<p>ADVATE is a medicine used to replace clotting factor (factor VIII
                            or antihemophilic factor) that is missing in people with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>
                            (also called “classic? <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span>). The product does not contain plasma
                            or albumin. <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">Hemophilia A</span> is an inherited <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorder that prevents
                            blood from clotting normally.</p>
<p>ADVATE is used to prevent and control <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in adults and
                            children (0-16 years) with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>.</p>
<p>Your healthcare provider may give you ADVATE when you have
                            surgery. </p>
<p>ADVATE can reduce the number of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes in adults and
                            children (0-16 years) when used regularly (prophylaxis).</p>
<p>ADVATE is not used to treat von Willebrand disease.</p>
<p><span class="Bold">Who should not use ADVATE?</span></p>
<p>You should not use ADVATE if you: </p>
<dl>
<dt>•</dt>
<dd>Are allergic to mice or hamsters.</dd>
<dt>•</dt>
<dd>Are allergic to any ingredients in
                                ADVATE.</dd>
</dl>
<p>Tell your healthcare provider if you are pregnant or
                            breastfeeding because ADVATE may not be right for you.</p>
<p><span class="Bold">How should I use ADVATE?</span></p>
<p>ADVATE is given directly into the bloodstream.</p>
<p>You may infuse ADVATE at a <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> treatment center, at your
                            healthcare provider’s office or in your home. You should be trained on
                            how to do infusions by your healthcare provider or <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> treatment
                            center. Many people with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> learn to infuse their ADVATE by
                            themselves or with the help of a family member.</p>
<p>Your healthcare provider will tell you how much ADVATE to use
                            based on your weight, the severity of your <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>, and where you
                            are <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>You may have to have blood tests done after getting ADVATE to be
                            sure that your blood level of factor VIII is high enough to clot your
                            blood.</p>
<p>Call your healthcare provider right away if your <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> does
                            not stop after taking ADVATE.</p>
<p><span class="Bold">What should I tell my healthcare provider
                                before I use ADVATE?</span></p>
<p>You should tell your healthcare provider if you:</p>
<dl>
<dt>•</dt>
<dd>Have or have had any medical problems.</dd>
<dt>•</dt>
<dd>Take any medicines, including prescription and
                                non-prescription medicines, such as over-the-counter medicines,
                                supplements or herbal remedies.</dd>
<dt>•</dt>
<dd>Have any allergies, including allergies to
                                mice or hamsters.</dd>
<dt>•</dt>
<dd>Are breastfeeding. It is not known if ADVATE
                                passes into your milk and if it can harm your baby.</dd>
<dt>•</dt>
<dd>Are pregnant or planning to become pregnant.
                                It is not known if ADVATE may harm your unborn baby.</dd>
<dt>•</dt>
<dd>Have been told that you have inhibitors to
                                factor VIII (because ADVATE may not work for you).</dd>
</dl>
<p><span class="Bold">What are the possible side effects of
                                ADVATE?</span></p>
<p>You can have an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to ADVATE.</p>
<p>Call your healthcare provider right away and stop treatment if
                            you get a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, tightness of the throat, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or
                            tightness, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or
                            <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>. </p>
<p>Side effects that have been reported with ADVATE
                            include:</p>
<table width="100%">
<col width="18%">
<col width="12%">
<col width="23%">
<tbody class="Headless">
<tr class="First Toprule">
<td><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>/aching</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of legs</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span>/congestion</p></td>
</tr>
<tr class="Botrule Last">
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p></td>
</tr>
</tbody>
</table>
<p>Tell your healthcare provider about any side effects that bother
                            you or do not go away.</p>
<p>These are not all the possible side effects with ADVATE. You can
                            ask your healthcare provider for information that is written for
                            healthcare professionals.</p>
<p><span class="Bold">What are the ADVATE dosage
                                strengths?</span></p>
<p>ADVATE with 2 mL or 5 mL Sterile Water for Injection in a BAXJECT
                            III system comes in six different dosage strengths: 250 International
                            Units (IU), 500 IU, 1000 IU, 1500 IU, 2000 IU, 3000 IU and 4000 IU. The
                            actual strength will be imprinted on the label on the housing and on the
                            box. The six different strengths are color coded, as
                            follows:</p>
<table width="100%">
<col width="18%">
<col width="57%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center">
<a name="id2788"></a><img alt="Light Blue" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-06.jpg">
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Dosage strength of approximately 250
                                            International Units <br>(200 – 400 IU) ( with 2 mL
                                            sWFI)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">
<a name="id2794"></a><img alt="Pink" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-07.jpg">
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Dosage strength of approximately 500
                                            International Units <br>(401 – 800 IU) ( with 2 mL
                                            sWFI)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">
<a name="id2800"></a><img alt="Green" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-08.jpg">
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Dosage strength of approximately 1000
                                            International Units <br>(801 – 1200 IU) ( with 2 mL
                                            sWFI)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">
<a name="id2806"></a><img alt="Purple" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-09.jpg">
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Dosage strength of approximately 1500
                                            International Units <br>(1201 – 1800 IU) ( with 2 mL
                                            sWFI)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">
<a name="id2812"></a><img alt="Orange" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-10.jpg">
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Dosage strength of approximately 2000
                                            International Units <br>(1801 – 2400 IU) (with 5 mL
                                            sWFI)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">
<a name="id2818"></a><img alt="Silver" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-11.jpg">
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Dosage strength of approximately 3000
                                            International Units <br>(2401 – 3600 IU) (with 5 mL
                                            sWFI)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center">
<a name="id2824"></a><img alt="Dark Green" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-12.jpg">
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Dosage strength of approximately 4000
                                            International Units <br>(3601 – 4800 IU) (with 5 mL
                                            sWFI)</p></td>
</tr>
</tbody>
</table>
<p>Always check the actual dosage strength printed on the label to
                            make sure you are using the strength prescribed by your healthcare
                            provider. Always check the expiration date printed on the box. Do not
                            use the product after the expiration date printed on the
                            box.</p>
<p><span class="Bold">How do I store ADVATE?</span></p>
<p>Do not freeze ADVATE.</p>
<p>Store ADVATE in a refrigerator (2° to 8°C [36° to 46°F]) or at
                            room temperature (up to 30°C [86°F]) for up to 6 months.</p>
<p>If you choose to store ADVATE at room temperature:</p>
<dl>
<dt>•</dt>
<dd>Note the date that the product is removed from
                                refrigeration on the box.</dd>
<dt>•</dt>
<dd>Do not use after six months from this date or
                                after the expiration date.</dd>
<dt>•</dt>
<dd>Do not return the product back to the
                                refrigerator.</dd>
</dl>
<p>Store ADVATE in the original box and protect from extreme
                            exposure to light. </p>
<p>Reconstituted product (after mixing dry product with wet diluent)
                            must be used within 3 hours and cannot be stored or refrigerated.
                            Discard any unused ADVATE at the end of your infusion.</p>
<p><span class="Bold">What else should I know about ADVATE and
                                <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">Hemophilia A</span>?</span></p>
<p>Your body may form inhibitors to factor VIII. An inhibitor is
                            part of the body’s normal defense system. If you form inhibitors, it may
                            stop ADVATE from working properly. Consult with your healthcare provider
                            to make sure you are carefully monitored with blood tests for the
                            development of inhibitors to factor VIII.</p>
<p>Medicines are sometimes prescribed for purposes other than those
                            listed here. Do not use ADVATE for a condition for which it is not
                            prescribed. Do not share ADVATE with other people, even if they have the
                            same symptoms that you have.</p>
<p><span class="Bold">Baxter Healthcare
                                Corporation<br></span>Westlake Village, CA 91362 USA<br>U.S.
                            License No. 140<br></p>
<p>Issued: 05/2015</p>
<p><span class="Bold">INSTRUCTIONS FOR USE</span></p>
<p><span class="Bold">ADVATE</span><br><span class="Bold">[Antihemophilic Factor
                                (Recombinant)]</span><br><span class="Bold">(For intravenous use only)</span></p>
<p><span class="Bold">Do not attempt to do an infusion to yourself
                                unless you have been taught how by your healthcare provider or
                                <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> center.</span></p>
<p>See below for step-by-step instructions for reconstituting ADVATE
                            in a BAXJECT III system. </p>
<dl>
<dt>•</dt>
<dd>Always follow the specific instructions given
                                by your healthcare provider. The steps listed below are general
                                guidelines for using ADVATE. If you are unsure of the procedures,
                                please call your healthcare provider before using. </dd>
<dt>•</dt>
<dd>Call your healthcare provider right away if
                                <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is not controlled after using ADVATE. </dd>
<dt>•</dt>
<dd>Your healthcare provider will prescribe the
                                dose that you should take. </dd>
<dt>•</dt>
<dd>Your healthcare provider may need to take
                                blood tests from time to time. </dd>
<dt>•</dt>
<dd>Talk to your healthcare provider before
                                traveling. Plan to bring enough ADVATE for your treatment during
                                this time.</dd>
<dt>•</dt>
<dd>Dispose of all materials, including any
                                leftover reconstituted ADVATE product, in an appropriate
                                container.</dd>
<dt>1.</dt>
<dd>Prepare a clean flat surface and gather all
                                the materials you will need for the infusion. Check the expiration
                                date, and let the ADVATE warm up to room temperature. Wash your
                                hands and put on clean exam gloves. If infusing yourself at home,
                                the use of gloves is optional. </dd>
<dt>2.</dt>
<dd>Open the ADVATE package by <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> away the
                                lid. Remove the ADVATE from the package and visually inspect the
                                contents of the product and diluent vial. The ADVATE powder should
                                be white to off-white in color and the diluent should not contain
                                particles. Do not use if discoloration or particles are seen.</dd>
<dt>3.</dt>
<dd>Place on a flat surface with the diluent vial
                                on top. The diluent vial has a blue stripe.</dd>
</dl>
<div class="Figure">
<a name="id2877"></a><img alt="Image 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-13.jpg">
</div>
<dl>
<dt>4.</dt>
<dd>With one hand holding the ADVATE housing,
                                press down firmly on the diluent vial with the other hand until the
                                system is fully collapsed and the diluent flows down into the ADVATE
                                vial. Both vials will move into the housing when pressed. If you
                                don’t see the diluent transfer to the product vial, press the vials
                                again to assure they are completely inserted. <span class="Underline">Do not remove the blue cap</span> until
                                instructed in a later step.</dd>
</dl>
<div class="Figure">
<a name="id2882"></a><img alt="Image 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-14.jpg">
</div>
<dl>
<dt>5.</dt>
<dd>Swirl the ADVATE gently and continuously
                                until the ADVATE is completely dissolved. <span class="Underline">Do not shake</span>. <span class="Underline">Do not refrigerate after
                                    reconstitution</span>. Inspect the ADVATE solution for
                                particulate matter and discoloration prior to administration. The
                                solution should be clear and colorless in appearance. If not, do not
                                use the solution and notify your healthcare provider
                                immediately.</dd>
</dl>
<div class="Figure">
<a name="id2888"></a><img alt="Image 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-15.jpg">
</div>
<dl>
<dt>6.</dt>
<dd>Take off the blue cap from the housing and
                                connect the syringe. Be careful to not inject air into the
                                ADVATE.</dd>
</dl>
<div class="Figure">
<a name="id2892"></a><img alt="Image 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-16.jpg">
</div>
<dl>
<dt>7.</dt>
<dd>Turn over the ADVATE so that the vial
                                containing the ADVATE solution is on top. Draw the ADVATE solution
                                into the syringe by pulling back the plunger slowly. If the solution
                                does not draw into the syringe, be sure that both vials are pressed
                                firmly together. The contents of more than one vial may be drawn
                                into a single, appropriately sized syringe if you are using more
                                than one vial of ADVATE.</dd>
</dl>
<div class="Figure">
<a name="id2896"></a><img alt="Image 7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-17.jpg">
</div>
<dl>
<dt>8.</dt>
<dd>Disconnect the syringe from the system.
                                Attach the infusion needle to the syringe using a winged (butterfly)
                                infusion set, if available. Point the needle up and remove any air
                                bubbles by gently tapping the syringe with your finger and slowly
                                and carefully pushing air out of the syringe and needle.</dd>
<dt>9.</dt>
<dd>Apply a tourniquet and get the injection site
                                ready by wiping the skin well with an alcohol swab (or other
                                suitable solution suggested by your healthcare provider or
                                <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> center).</dd>
</dl>
<div class="Figure">
<a name="id2901"></a><img alt="Image 9" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-18.jpg">
</div>
<dl>
<dt>10.</dt>
<dd>Insert the needle into the vein and remove
                                the tourniquet. Slowly infuse the ADVATE. <span class="Underline">Do not infuse any faster than 10 mL per
                                    minute</span>.</dd>
</dl>
<div class="Figure">
<a name="id2952"></a><img alt="Image 10" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-19.jpg">
</div>
<dl>
<dt>11.</dt>
<dd>Take the needle out of the vein and use
                                sterile gauze to put pressure on the infusion site for several
                                minutes.</dd>
<dt>12.</dt>
<dd>
<span class="Bold">Do not recap the
                                    needle. </span>Place the needle, syringe, and ADVATE in a
                                hard-walled sharps container for proper disposal. Do not dispose of
                                these supplies in ordinary household trash.</dd>
<dt>13.</dt>
<dd>Remove the peel-off label from the housing
                                and place it in your logbook. Clean any spilled blood with a freshly
                                prepared mixture of 1 part bleach and 9 parts water, soap and water,
                                or any household disinfecting solution.</dd>
</dl>
<p><span class="Underline">Important: Contact your healthcare
                                provider or local <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> treatment center if you experience any
                                problems</span>.</p>
<p>Baxter, Advate, and Baxject are trademarks of Baxter
                            International Inc. registered in the U.S. Patent and Trademark Office. </p>
<p>Patented: see <a href="http://www.baxter.com/productpatents/">www.baxter.com/productpatents/</a></p>
<p><span class="Bold">Baxter Healthcare
                            Corporation</span><br>Westlake Village, CA 91362 USA<br>U.S.
                            License No. 140<br><br>Issued May 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_f858c897-e7b5-4ee4-9a9a-a45adcbbc0e5"></a><a name="section-16"></a><p></p>
<h1>Principal Display Panel</h1>
<div class="Figure">
<a name="id2976"></a><img alt="250 IU <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-20.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack 250 IU 2 mL </p>
</div>
<p class="First">ADVATE BAXJECT III <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack 250 IU 2 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p>NDC 0944-3051-03</p>
<p>Single use only</p>
<p><span class="Bold">For Intravenous Administration Only</span></p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>Do not open until time of use</p>
<p>Do not use if packaging is opened or damaged</p>
<p><span class="Bold">Rx Only</span></p>
<p>2 mL</p>
<div class="Figure">
<a name="id2993"></a><img alt="250 IU Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-21.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III Unit Carton 250 IU 2 mL </p>
</div>
<p>ADVATE BAXJECT III Unit Carton 250 IU 2 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p>NDC 0944-3051-02</p>
<p>Single use only</p>
<p><span class="Bold">For Intravenous Administration Only</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Lyophilized powder for reconstitution</p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>2 mL</p>
<div class="Figure">
<a name="id3009"></a><img alt="250 IU Barrel Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-22.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III Barrel Label 250 IU 2 mL </p>
</div>
<p>ADVATE BAXJECT III Barrel Label 250 IU 2 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p><span class="Bold">For Intravenous Administration Only</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>Directions for use: see package insert</p>
<div class="Figure">
<a name="id3022"></a><img alt="500 IU <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-23.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack 500 IU 2 mL </p>
</div>
<p>ADVATE BAXJECT III <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack 500 IU 2 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p>NDC 0944-3052-03</p>
<p>Single use only</p>
<p><span class="Bold">For Intravenous Administration Only</span></p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>Do not open until time of use</p>
<p>Do not use if packaging is opened or damaged</p>
<p><span class="Bold">Rx Only</span></p>
<p>2 mL</p>
<div class="Figure">
<a name="id3039"></a><img alt="500 IU Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-24.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III Unit Carton 500 IU 2 mL </p>
</div>
<p>ADVATE BAXJECT III Unit Carton 500 IU 2 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p>NDC 0944-3052-02</p>
<p>Single use only</p>
<p><span class="Bold">For Intravenous Administration Only</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Lyophilized powder for reconstitution</p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>2 mL</p>
<div class="Figure">
<a name="id3056"></a><img alt="500 IU Barrel Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-25.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III Barrel Label 500 IU 2 mL </p>
</div>
<p>ADVATE BAXJECT III Barrel Label 500 IU 2 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p><span class="Bold">For Intravenous Administration Only</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Lyophilized powder for reconstitution</p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>Directions for use: see package insert</p>
<div class="Figure">
<a name="id3070"></a><img alt="1000 IU <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-26.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack 1000 IU 2 mL </p>
</div>
<p>ADVATE BAXJECT III <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack 1000 IU 2 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p><span class="Bold">For Intravenous Administration Only</span></p>
<p>NDC 0944-3053-03</p>
<p>Single use only</p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>Do not open until time of use</p>
<p>Do not use if packaging is opened or damaged</p>
<p><span class="Bold">Rx Only</span></p>
<p>2 mL</p>
<div class="Figure">
<a name="id3087"></a><img alt="1000 IU Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-27.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III Unit Carton 1000 IU 2 mL </p>
</div>
<p>ADVATE BAXJECT III Unit Carton 1000 IU 2 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p>NDC 0944-3053-02</p>
<p>Single use only</p>
<p><span class="Bold">For Intravenous Administration Only</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Lyophilized powder for reconstitution</p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>2 mL</p>
<div class="Figure">
<a name="id3103"></a><img alt="1000 IU Barrel Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-28.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III Barrel Label 1000 IU 2 mL </p>
</div>
<p>ADVATE BAXJECT III Barrel Label 1000 IU 2 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p><span class="Bold">For Intravenous Administration Only</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>Directions for use: see package insert</p>
<div class="Figure">
<a name="id3116"></a><img alt="1500 IU <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-29.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack 1500 IU 2 mL </p>
</div>
<p>ADVATE BAXJECT III <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack 1500 IU 2 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p><span class="Bold">For Intravenous Administration Only</span></p>
<p>NDC 0944-3054-03</p>
<p>Single use only</p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>Do not open until time of use</p>
<p>Do not use if packaging is opened or damaged</p>
<p><span class="Bold">Rx Only</span></p>
<p>2 mL</p>
<div class="Figure">
<a name="id3133"></a><img alt="1500 IU Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-30.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III Unit Carton 1500 IU 2 mL </p>
</div>
<p>ADVATE BAXJECT III Unit Carton 1500 IU 2 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p>NDC 0944-3054-02</p>
<p>Single use only</p>
<p><span class="Bold">For Intravenous Administration Only</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Lyophilized powder for reconstitution</p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>2 mL</p>
<div class="Figure">
<a name="id3150"></a><img alt="1500 IU Barrel Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-31.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III Barrel Label 1500 IU 2 mL </p>
</div>
<p>ADVATE BAXJECT III Barrel Label 1500 IU 2 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p><span class="Bold">For intravenous Administration Only</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>Directions for use: see package insert</p>
<div class="Figure">
<a name="id3163"></a><img alt="2000 IU <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-32.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack 2000 IU 5 mL </p>
</div>
<p>ADVATE BAXJECT III <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack 2000 IU 5 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p><span class="Bold">For Intravenous Administration Only</span></p>
<p>NDC 0944-3045-11</p>
<p>Single use only</p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>Do not open until time of use</p>
<p>Do not use if packaging is opened or damaged</p>
<p><span class="Bold">Rx Only</span></p>
<p>5 mL</p>
<div class="Figure">
<a name="id3180"></a><img alt="2000 IU Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-33.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III Unit Carton 2000 IU 5 mL </p>
</div>
<p>ADVATE BAXJECT III Unit Carton 2000 IU 5 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p>NDC 0944-3045-10</p>
<p>Single use only</p>
<p><span class="Bold">For Intravenous Administration Only</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Lyophilized powder for reconstitution</p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>5 mL</p>
<div class="Figure">
<a name="id3197"></a><img alt="2000 IU Barrel Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-34.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III Barrel Label 2000 IU 5 mL </p>
</div>
<p>ADVATE BAXJECT III Barrel Label 2000 IU 5 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p><span class="Bold">For Intravenous Administration Only</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>Directions for use: see package insert</p>
<div class="Figure">
<a name="id3210"></a><img alt="3000 IU <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-35.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack 3000 IU 5 mL </p>
</div>
<p>ADVATE BAXJECT III <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack 3000 IU 5 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p><span class="Bold">For intravenous Administration Only</span></p>
<p>NDC 0944-3046-11</p>
<p>Single use only</p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>Do not open until time of use</p>
<p>Do not use if packaging is opened or damaged</p>
<p><span class="Bold">Rx Only</span></p>
<p>5 mL</p>
<div class="Figure">
<a name="id3227"></a><img alt="3000 IU Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-36.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III Unit Carton 3000 IU 5 mL </p>
</div>
<p>ADVATE BAXJECT III Unit Carton 3000 IU 5 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p>NDC 0944-3046-10</p>
<p>Single use only</p>
<p><span class="Bold">For Intravenous Administration Only</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Lyophilized powder for reconstitution</p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>5 mL</p>
<div class="Figure">
<a name="id3244"></a><img alt="3000 IU Barrel Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-37.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III Barrel Label 3000 IU 5 mL </p>
</div>
<p>ADVATE BAXJECT III Barrel Label 3000 IU 5 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p><span class="Bold">For intravenous Administration Only</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>Directions for use: see package insert</p>
<div class="Figure">
<a name="id3257"></a><img alt="4000 IU <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-38.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack 4000 IU 5 mL </p>
</div>
<p>ADVATE BAXJECT III <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack 4000 IU 5 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p><span class="Bold">For intravenous Administration Only</span></p>
<p>NDC 0944-3047-11</p>
<p>Single use only</p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>Do not open until time of use</p>
<p>Do not use if packaging is opened or damaged</p>
<p><span class="Bold">Rx Only</span></p>
<p>5 mL</p>
<div class="Figure">
<a name="id3274"></a><img alt="4000 IU Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-39.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III 4000 IU 5 mL </p>
</div>
<p>ADVATE BAXJECT III 4000 IU 5 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p>NDC 0944-3047-10</p>
<p>Single use only</p>
<p><span class="Bold">For Intravenous Administration Only</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>5 mL</p>
<div class="Figure">
<a name="id3289"></a><img alt="4000 IU Barrel Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da&amp;name=image-40.jpg"><p class="MultiMediaCaption">ADVATE BAXJECT III Barrel Label 4000 IU 5 mL </p>
</div>
<p>ADVATE BAXJECT III Barrel Label 4000 IU 5 mL </p>
<p><span class="Bold">ADVATE</span></p>
<p><span class="Bold">[Antihemophilic Factor (Recombinant),
                                Plasma/Albumin-Free Method]</span></p>
<p><span class="Bold">For intravenous Administration Only</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>ADVATE and diluent preassembled in BAXJECT III system</p>
<p>Directions for use: see package insert</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADVATE 		
					</strong><br><span class="contentTableReg">antihemophilic factor, human recombinant kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-3051</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3051-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3051-03</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3051-04</td>
<td class="formItem">1  in 1 CONTAINER; Combination Product Type = C102842</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">5 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">2 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ADVATE 		
					</strong><br><span class="contentTableReg">antihemophilic factor, human
                                                  recombinant injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-2941</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT</strong> (ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT) </td>
<td class="formItem">ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT</td>
<td class="formItem">50 [iU]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLUTATHIONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TREHALOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TROMETHAMINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-2941-01</td>
<td class="formItem">5 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">water liquid</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52919-008</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">2 mL  in 2 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52919-008-05</td>
<td class="formItem">2 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">07/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADVATE 		
					</strong><br><span class="contentTableReg">antihemophilic factor, human recombinant kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-3052</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3052-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3052-03</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3052-04</td>
<td class="formItem">1  in 1 CONTAINER; Combination Product Type = C102842</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">5 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">2 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ADVATE 		
					</strong><br><span class="contentTableReg">antihemophilic factor, human
                                                  recombinant injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-2942</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT</strong> (ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT) </td>
<td class="formItem">ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT</td>
<td class="formItem">100 [iU]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLUTATHIONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TREHALOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TROMETHAMINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-2942-01</td>
<td class="formItem">5 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">water liquid</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52919-008</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">2 mL  in 2 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52919-008-05</td>
<td class="formItem">2 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADVATE 		
					</strong><br><span class="contentTableReg">antihemophilic factor, human recombinant kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-3053</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3053-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3053-04</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3053-03</td>
<td class="formItem">1  in 1 CONTAINER; Combination Product Type = C102842</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">5 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">2 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ADVATE 		
					</strong><br><span class="contentTableReg">antihemophilic factor, human
                                                  recombinant injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-2943</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT</strong> (ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT) </td>
<td class="formItem">ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT</td>
<td class="formItem">200 [iU]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLUTATHIONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TREHALOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TROMETHAMINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-2943-01</td>
<td class="formItem">5 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">water liquid</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52919-008</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem">2 mL  in 2 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52919-008-05</td>
<td class="formItem">2 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADVATE 		
					</strong><br><span class="contentTableReg">antihemophilic factor, human recombinant kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-3054</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3054-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3054-03</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3054-04</td>
<td class="formItem">1  in 1 CONTAINER; Combination Product Type = C102842</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">5 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">2 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ADVATE 		
					</strong><br><span class="contentTableReg">antihemophilic factor, human
                                                  recombinant injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-2944</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT</strong> (ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT) </td>
<td class="formItem">ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT</td>
<td class="formItem">300 [iU]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLUTATHIONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TREHALOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TROMETHAMINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-2944-01</td>
<td class="formItem">5 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">water liquid</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52919-008</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">2 mL  in 2 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52919-008-05</td>
<td class="formItem">2 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADVATE 		
					</strong><br><span class="contentTableReg">antihemophilic factor, human recombinant kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-3045</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3045-10</td>
<td class="formItem">1  in 1 CONTAINER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3045-12</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3045-11</td>
<td class="formItem">1  in 1 CONTAINER; Combination Product Type = C102842</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">5 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ADVATE 		
					</strong><br><span class="contentTableReg">antihemophilic factor, human
                                                  recombinant injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-2945</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT</strong> (ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT) </td>
<td class="formItem">ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT</td>
<td class="formItem">400 [iU]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLUTATHIONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TREHALOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TROMETHAMINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-2945-01</td>
<td class="formItem">5 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">water liquid</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-0001</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">5 mL  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-0001-56</td>
<td class="formItem">5 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADVATE 		
					</strong><br><span class="contentTableReg">antihemophilic factor, human recombinant kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-3046</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3046-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3046-12</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3046-11</td>
<td class="formItem">1  in 1 CONTAINER; Combination Product Type = C102842</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">5 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ADVATE 		
					</strong><br><span class="contentTableReg">antihemophilic factor, human
                                                  recombinant injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-2946</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT</strong> (ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT) </td>
<td class="formItem">ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT</td>
<td class="formItem">600 [iU]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLUTATHIONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TREHALOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TROMETHAMINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-2946-01</td>
<td class="formItem">5 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">water liquid</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-0001</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem">5 mL  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-0001-56</td>
<td class="formItem">5 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">07/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADVATE 		
					</strong><br><span class="contentTableReg">antihemophilic factor, human recombinant kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-3047</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3047-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3047-12</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-3047-11</td>
<td class="formItem">1  in 1 CONTAINER; Combination Product Type = C102842</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">5 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ADVATE 		
					</strong><br><span class="contentTableReg">antihemophilic factor, human
                                                  recombinant injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-2947</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT</strong> (ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT) </td>
<td class="formItem">ANTIHEMOPHILIC FACTOR, HUMAN
                                                  RECOMBINANT</td>
<td class="formItem">800 [iU]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLUTATHIONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TREHALOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TROMETHAMINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-2947-01</td>
<td class="formItem">5 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">02/04/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">water liquid</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-0001</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">5 mL  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-0001-56</td>
<td class="formItem">5 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125063</td>
<td class="formItem">06/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation
							(039121363)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BAXTER HEALTHCARE CORPORATION</td>
<td class="formItem"></td>
<td class="formItem">009471603</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Hameln Pharmaceutical GmbH</td>
<td class="formItem"></td>
<td class="formItem">315869123</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">001728059</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>406bee74-c9b6-4b81-a143-c01b39d6608f</div>
<div>Set id: 80fa03d2-cd4c-4155-9b57-1396c4fa42da</div>
<div>Version: 2</div>
<div>Effective Time: 20150505</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
